Alzheimer's disease drug development pipeline: 2022
2022; Elsevier BV; Volume: 8; Issue: 1 Linguagem: Inglês
10.1002/trc2.12295
ISSN2352-8737
AutoresJeffrey L. Cummings, Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Ramón Fonseca Cacho, Kazem Taghva,
Tópico(s)Cancer-related cognitive impairment studies
ResumoAlzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD.
Referência(s)